Can we protect the gut in critical illness? The role of growth factors and other novel approaches

Critical Care Clinics

Volumn 26, Issue 3, 2010, Pages 549-565

  Dominguez, Jessica A ^a   Coopersmith, Craig M ^b  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Critical illness; Growth factors; Intestine

Indexed keywords

ADENOVIRUS VECTOR; CLAUDIN 2; EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; FAS ASSOCIATED DEATH DOMAIN PROTEIN; GLUCAGON LIKE PEPTIDE 2; GLUTAMINE; GROWTH FACTOR; GROWTH HORMONE; HEPARIN BINDING EPIDERMAL GROWTH FACTOR; HISTIDYL DEXTRO TRYPTOPHYLALANYLTRYPTOPHYL DEXTRO PHENYLALANYLLYSINAMIDE; INTESTINAL TREFOIL FACTOR; KERATINOCYTE GROWTH FACTOR; PROTEIN BCL 2; PROTEIN BID; PROTEIN P21; RECOMBINANT KERATINOCYTE GROWTH FACTOR; RECOMBINANT SCATTER FACTOR; SCATTER FACTOR; SOMATOMEDIN C;

APOPTOSIS; CELL DIFFERENTIATION; CELL MIGRATION; CELL PROLIFERATION; CELL SURVIVAL; CLINICAL TRIAL; COLITIS; CONTINUOUS INFUSION; CRITICAL ILLNESS; DIGESTIVE SYSTEM INJURY; ELECTROLYTE DISTURBANCE; ENTERITIS; HEART ARREST; HEMORRHAGIC SHOCK; HUMAN; HYPOGLYCEMIA; INTENSIVE CARE; INTESTINE; INTESTINE EPITHELIUM; INTESTINE INJURY; LUNG INJURY; MEDIATOR RELEASE; MESENTERY LYMPH NODE; NONHUMAN; PERFUSION; PRIORITY JOURNAL; PROTEIN EXPRESSION; REPERFUSION; REVIEW; SEPSIS; SHOCK; STOMACH INJURY; SURVIVAL; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; TIGHT JUNCTION; ULCERATIVE COLITIS;

CRITICAL ILLNESS; GASTROINTESTINAL TRACT; HUMANS; INTENSIVE CARE; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME;

EID: 77954910747     PISSN: 07490704     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ccc.2010.04.005     Document Type: Review

References (140)

1. Hassoun H.T., Kone B.C., Mercer D.W., et al. Post-injury multiple organ failure: the role of the gut. Shock 2001, 15:1-10.
2. Alverdy J.C., Laughlin R.S., Wu L. Influence of the critically ill state on host-pathogen interactions within the intestine: gut-derived sepsis redefined. Crit Care Med 2003, 31:598-607.
3. Fink M.P. Intestinal epithelial hyperpermeability: update on the pathogenesis of gut mucosal barrier dysfunction in critical illness. Curr Opin Crit Care 2003, 9:143-151.
4. Han X., Fink M.P., Yang R., et al. Increased iNOS activity is essential for intestinal epithelial tight junction dysfunction in endotoxemic mice. Shock 2004, 21:261-270.
5. Fink M.P., Delude R.L. Epithelial barrier dysfunction: a unifying theme to explain the pathogenesis of multiple organ dysfunction at the cellular level. Crit Care Clin 2005, 21:177-196.
6. Deitch E.A., Xu D., Kaise V.L. Role of the gut in the development of injury- and shock induced SIRS and MODS: the gut-lymph hypothesis, a review. Front Biosci 2006, 11:520-528.
7. Coopersmith C.M., Stromberg P.E., Dunne W.M., et al. Inhibition of intestinal epithelial apoptosis and survival in a murine model of pneumonia-induced sepsis. JAMA 2002, 287:1716-1721.
8. Coopersmith C.M., Chang K.C., Swanson P.E., et al. Overexpression of Bcl-2 in the intestinal epithelium improves survival in septic mice. Crit Care Med 2002, 30:195-201.
9. Cheng H., Leblond C.P. Origin, differentiation and renewal of the four main epithelial cell types in the mouse small intestine. V. Unitarian theory of the origin of the four epithelial cell types. Am J Anat 1974, 141:537-561.
10. Hall P.A., Coates P.J., Ansari B., et al. Regulation of cell number in the mammalian gastrointestinal tract: the importance of apoptosis. J Cell Sci 1994, 107(Pt 12):3569-3577.
11. Utech M., Bruwer M., Nusrat A. Tight junctions and cell-cell interactions. Methods Mol Biol 2006, 341:185-195.
12. Johnson L.G. Applications of imaging techniques to studies of epithelial tight junctions. Adv Drug Deliv Rev 2005, 57:111-121.
13. Mammen J.M.V.M., Matthews J.B.M. Mucosal repair in the gastrointestinal tract. Crit Care Med 2003, 31:S532-S537. [miscellaneous].
14. Nusrat A., Delp C., Madara J.L. Intestinal epithelial restitution. Characterization of a cell culture model and mapping of cytoskeletal elements in migrating cells. J Clin Invest 1992, 89:1501-1511.
15. Moore R., Carlson S., Madara J.L. Rapid barrier restitution in an in vitro model of intestinal epithelial injury. Lab Invest 1989, 60:237-244.
16. Dignass A.U. Mechanisms and modulation of intestinal epithelial repair. Inflamm Bowel Dis 2001, 7:68-77.
17. Grenier A., Chollet-Martin S., Crestani B., et al. Presence of a mobilizable intracellular pool of hepatocyte growth factor in human polymorphonuclear neutrophils. Blood 2002, 99:2997-3004.
18. Oka Y., Orth D.N. Human plasma epidermal growth factor/beta-urogastrone is associated with blood platelets. J Clin Invest 1983, 72:249-259.
19. Karey K.P., Marquardt H., Sirbasku D.A. Human platelet-derived mitogens. I. Identification of insulinlike growth factors I and II by purification and N alpha amino acid sequence analysis. Blood 1989, 74:1084-1092.
20. Nakamura T., Nawa K., Ichihara A., et al. Purification and subunit structure of hepatocyte growth factor from rat platelets. FEBS Lett 1987, 224:311-316.
21. Playford R.J., Wright N.A. Why is epidermal growth factor present in the gut lumen?. Gut 1996, 38:303-305.
22. Jones M.K., Tomikawa M., Mohajer B., et al. Gastrointestinal mucosal regeneration: role of growth factors. Front Biosci 1999, 4:D303-D309.
23. Abud H.E., Watson N., Heath J.K. Growth of intestinal epithelium in organ culture is dependent on EGF signalling. Exp Cell Res 2005, 303:252-262.
24. Miettinen P.J., Berger J.E., Meneses J., et al. Epithelial immaturity and multiorgan failure in mice lacking epidermal growth factor receptor. Nature 1995, 376:337-341.
25. Tepperman B.L., Soper B.D. Effect of epidermal growth factor, transforming growth factor alpha and nerve growth factor on gastric mucosal integrity and microcirculation in the rat. Regul Pept 1994, 50:13-21.
26. Bernal N.P., Stehr W., Coyle R., et al. Epidermal growth factor receptor signaling regulates Bax and Bcl-w expression and apoptotic responses during intestinal adaptation in mice. Gastroenterology 2006, 130:412-423.
27. Clark J.A., Lane R.H., Maclennan N.K., et al. Epidermal growth factor reduces intestinal apoptosis in an experimental model of necrotizing enterocolitis. Am J Physiol Gastrointest Liver Physiol 2005, 288:G755-G762.
28. Halpern M.D., Dominguez J.A., Dvorakova K., et al. Ileal cytokine dysregulation in experimental necrotizing enterocolitis is reduced by epidermal growth factor. J Pediatr Gastroenterol Nutr 2003, 36:126-133.
29. Clark J.A., Doelle S.M., Halpern M.D., et al. Intestinal barrier failure during experimental necrotizing enterocolitis: protective effect of EGF treatment. Am J Physiol Gastrointest Liver Physiol 2006, 291:G938-G949.
30. Clark J.A., Gan H., Samocha A.J., et al. Enterocyte-specific epidermal growth factor prevents barrier dysfunction and improves mortality in murine peritonitis. Am J Physiol Gastrointest Liver Physiol 2009, 297:G471-G479.
31. Clark J.A., Clark A.T., Hotchkiss R.S., et al. Epidermal growth factor treatment decreases mortality and is associated with improved gut integrity in sepsis. Shock 2008, 30:36-42.
32. Berlanga J., Prats P., Remirez D., et al. Prophylactic use of epidermal growth factor reduces ischemia/reperfusion intestinal damage. Am J Pathol 2002, 161:373-379.
33. Ishikawa T., Tarnawski A., Sarfeh I.J., et al. Epidermal growth factor protects gastric mucosa against ischemia-reperfusion injury. J Clin Gastroenterol 1993, 17(Suppl 1):S104-S110.
34. Berlanga J., Lodos J., Lopez-Saura P. Attenuation of internal organ damages by exogenously administered epidermal growth factor (EGF) in burned rodents. Burns 2002, 28:435-442.
35. Dvorak B., Halpern M.D., Holubec H., et al. Epidermal growth factor reduces the development of necrotizing enterocolitis in a neonatal rat model. Am J Physiol Gastrointest Liver Physiol 2002, 282:G156-G164.
36. Erwin C.R., Helmrath M.A., Shin C.E., et al. Intestinal overexpression of EGF in transgenic mice enhances adaptation after small bowel resection. Am J Physiol 1999, 277:G533-G540.
37. Chaet M.S., Arya G., Ziegler M.M., et al. Epidermal growth factor enhances intestinal adaptation after massive small bowel resection. J Pediatr Surg 1994, 29:1035-1038.
38. Helmrath M.A., Erwin C.R., Warner B.W. A defective EGF-receptor in waved-2 mice attenuates intestinal adaptation. J Surg Res 1997, 69:76-80.
39. Tarnawski A., Stachura J., Durbin T., et al. Increased expression of epidermal growth factor receptor during gastric ulcer healing in rats. Gastroenterology 1992, 102:695-698.
40. Itoh M., Matsuo Y. Gastric ulcer treatment with intravenous human epidermal growth factor: a double-blind controlled clinical study. J Gastroenterol Hepatol 1994, 9(Suppl 1):S78-S83.
41. Clinical trials. Other. 10-19-0009. 10-13-0009. Ref Type: Electronic Citation. Available at: Accessed October 13, 2009. http://clinicaltrials.gov/ct2/results?term=epidermal+growth+factor.
42. Sinha A., Nightingale J., West K.P., et al. Epidermal growth factor enemas with oral mesalamine for mild-to-moderate left-sided ulcerative colitis or proctitis. N Engl J Med 2003, 349:350-357.
43. Sullivan P.B., Lewindon P.J., Cheng C., et al. Intestinal mucosa remodeling by recombinant human epidermal growth factor(1-48) in neonates with severe necrotizing enterocolitis. J Pediatr Surg 2007, 42:462-469.
44. Teng C.T., Hinds C.J. Treatment with GH and IGF-1 in critical illness. Crit Care Clin 2006, 22:29-40. vi.
45. Lang C.H., Frost R.A. Role of growth hormone, insulin-like growth factor-I, and insulin-like growth factor binding proteins in the catabolic response to injury and infection [miscellaneous article]. Curr Opin Clin Nutr Metab Care 2002, 5:271-279.
46. Lal S.O., Wolf S.E., Herndon D.N. Growth hormone, burns and tissue healing. Growth Horm IGF Res 2000, 10(Suppl B):S39-S43.
47. Briard N., Dadoun F., Pommier G., et al. IGF-I/IGFBPs system response to endotoxin challenge in sheep. J Endocrinol 2000, 164:361-369.
48. Dahn M.S., Lange M.P. Systemic and splanchnic metabolic response to exogenous human growth hormone. Surgery 1998, 123:528-538.
49. ehaye-Zervas M.C., Mertani H., Martini J.F., et al. Expression of the growth hormone receptor gene in human digestive tissue. J Clin Endocrinol Metab 1994, 78:1473-1480.
50. Ulshen M.H., Dowling R.H., Fuller C.R., et al. Enhanced growth of small bowel in transgenic mice overexpressing bovine growth hormone. Gastroenterology 1993, 104:973-980.
51. Williams K.L., Fuller C.R., Dieleman L.A., et al. Enhanced survival and mucosal repair after dextran sodium sulfate-induced colitis in transgenic mice that overexpress growth hormone. Gastroenterology 2001, 120:925-937.
52. Gu Y., Wu Z.H., Xie J.X., et al. Effects of growth hormone (rhGH) and glutamine supplemented parenteral nutrition on intestinal adaptation in short bowel rats. Clin Nutr 2001, 20:159-166.
53. Waitzberg D.L., Cukier C., Mucerino D.R., et al. Small bowel adaptation with growth hormone and glutamine after massive resection of rat's small bowel. Nutr Hosp 1999, 14:81-90.
54. Peterson C.A., Gillingham M.B., Mohapatra N.K., et al. Enterotrophic effect of insulin-like growth factor-I but not growth hormone and localized expression of insulin-like growth factor-I, insulin-like growth factor binding protein-3 and -5 mRNAs in jejunum of parenterally fed rats. JPEN J Parenter Enteral Nutr 2000, 24:288-295.
55. Peterson C.A., Carey H.V., Hinton P.L., et al. GH elevates serum IGF-I levels but does not alter mucosal atrophy in parenterally fed rats. Am J Physiol 1997, 272:G1100-G1108.
56. Jeschke M.G., Herndon D.N., Finnerty C.C., et al. The effect of growth hormone on gut mucosal homeostasis and cellular mediators after severe trauma. J Surg Res 2005, 127:183-189.
57. Frost R.A., Lang C.H. Growth factors in critical illness: regulation and therapeutic aspects. Curr Opin Clin Nutr Metab Care 1998, 1:195-204. [miscellaneous article].
58. Baker J., Liu J.P., Robertson E.J., et al. Role of insulin-like growth factors in embryonic and postnatal growth. Cell 1993, 75:73-82.
59. Entingh-Pearsall A., Kahn C.R. Differential roles of the insulin and insulin-like growth factor-I (IGF-I) receptors in response to insulin and IGF-I. J Biol Chem 2004, 279:38016-38024.
60. Ohneda K., Ulshen M.H., Fuller C.R., et al. Enhanced growth of small bowel in transgenic mice expressing human insulin-like growth factor I. Gastroenterology 1997, 112:444-454.
61. Zhang W., Frankel W.L., Adamson W.T., et al. Insulin-like growth factor-I improves mucosal structure and function in transplanted rat small intestine. Transplantation 1995, 59:755-761.
62. Huang K.F., Chung D.H., Herndon D.N. Insulinlike growth factor 1 (IGF-1) reduces gut atrophy and bacterial translocation after severe burn injury. Arch Surg 1993, 128:47-53.
63. Fukushima R., Saito H., Inoue T., et al. Prophylactic treatment with growth hormone and insulin-like growth factor I improve systemic bacterial clearance and survival in a murine model of burn-induced gut-derived sepsis. Burns 1999, 25:425-430.
64. Ozen S., Akisu M., Baka M., et al. Insulin-like growth factor attenuates apoptosis and mucosal damage in hypoxia/reoxygenation-induced intestinal injury. Biol Neonate 2005, 87:91-96.
65. Baregamian N., Song J., Jeschke M.G., et al. IGF-1 protects intestinal epithelial cells from oxidative stress-induced apoptosis. J Surg Res 2006, 136:31-37.
66. Takala J., Ruokonen E., Webster N.R., et al. Increased mortality associated with growth hormone treatment in critically ill adults. N Engl J Med 1999, 341:785-792.
67. Taylor B.E., Buchman T.G. Is there a role for growth hormone therapy in refractory critical illness?. Curr Opin Crit Care 2008, 14:438-444.
68. Branski L.K., Herndon D.N., Barrow R.E., et al. Randomized controlled trial to determine the efficacy of long-term growth hormone treatment in severely burned children. Ann Surg 2009, [Epub ahead of print]. PMID: 19734776.
69. Jabri N., Schalch D.S., Schwartz S.L., et al. Adverse effects of recombinant human insulin-like growth factor I in obese insulin-resistant type II diabetic patients. Diabetes 1994, 43:369-374.
70. Bondy C.A., Underwood L.E., Clemmons D.R., et al. Clinical uses of insulin-like growth factor I. Ann Intern Med 1994, 120:593-601.
71. DebRoy M.A., Wolf S.E., Zhang X.J., et al. Anabolic effects of insulin-like growth factor in combination with insulin-like growth factor binding protein-3 in severely burned adults. J Trauma 1999, 47:904-910.
72. Herndon D.N., Ramzy P.I., DebRoy M.A., et al. Muscle protein catabolism after severe burn: effects of IGF-1/IGFBP-3 treatment. Ann Surg 1999, 229:713-720.
73. Jeschke M.G., Barrow R.E., Suzuki F., et al. IGF-I/IGFBP-3 equilibrates ratios of pro- to anti-inflammatory cytokines, which are predictors for organ function in severely burned pediatric patients. Mol Med 2002, 8:238-246.
74. Jeschke M.G., Barrow R.E., Herndon D.N. Insulinlike growth factor I plus insulinlike growth factor binding protein 3 attenuates the proinflammatory acute phase response in severely burned children. Ann Surg 2000, 231:246-252.
75. Jeschke M.G., Bolder U., Chung D.H., et al. Gut mucosal homeostasis and cellular mediators after severe thermal trauma and the effect of insulin-like growth factor-I in combination with insulin-like growth factor binding protein-3. Endocrinology 2007, 148:354-362.
76. Finch P.W., Rubin J.S., Miki T., et al. Human KGF is FGF-related with properties of a paracrine effector of epithelial cell growth. Science 1989, 245:752-755.
77. Brauchle M., Madlener M., Wagner A.D., et al. Keratinocyte growth factor is highly overexpressed in inflammatory bowel disease. Am J Pathol 1996, 149:521-529.
78. Housley R.M., Morris C.F., Boyle W., et al. Keratinocyte growth factor induces proliferation of hepatocytes and epithelial cells throughout the rat gastrointestinal tract. J Clin Invest 1994, 94:1764-1777.
79. Zeeh J.M., Procaccino F., Hoffmann P., et al. Keratinocyte growth factor ameliorates mucosal injury in an experimental model of colitis in rats. Gastroenterology 1996, 110:1077-1083.
80. Chen Y., Chou K., Fuchs E., et al. Protection of the intestinal mucosa by intraepithelial gamma delta T cells. Proc Natl Acad Sci U S A 2002, 99:14338-14343.
81. Wildhaber B.E., Yang H., Teitelbaum D.H. Keratinocyte growth factor decreases total parenteral nutrition-induced apoptosis in mouse intestinal epithelium via Bcl-2. J Pediatr Surg 2003, 38:92-96.
82. Finch P.W., Rubin J.S. Keratinocyte growth factor/fibroblast growth factor 7, a homeostatic factor with therapeutic potential for epithelial protection and repair. Adv Cancer Res 2004, 91:69-136.
83. Khan W.B., Shui C., Ning S., et al. Enhancement of murine intestinal stem cell survival after irradiation by keratinocyte growth factor. Radiat Res 1997, 148:248-253.
84. Farrell C.L., Bready J.V., Rex K.L., et al. Keratinocyte growth factor protects mice from chemotherapy and radiation-induced gastrointestinal injury and mortality. Cancer Res 1998, 58:933-939.
85. Sandborn W.J., Sands B.E., Wolf D.C., et al. Repifermin (keratinocyte growth factor-2) for the treatment of active ulcerative colitis: a randomized, double-blind, placebo-controlled, dose-escalation trial. Aliment Pharmacol Ther 2003, 17:1355-1364.
86. Kanayama M., Takahara T., Yata Y., et al. Hepatocyte growth factor promotes colonic epithelial regeneration via Akt signaling. Am J Physiol Gastrointest Liver Physiol 2007, 293:G230-G239.
87. Ido A., Numata M., Kodama M., et al. Mucosal repair and growth factors: recombinant human hepatocyte growth factor as an innovative therapy for inflammatory bowel disease. J Gastroenterol 2005, 40:925-931.
88. Nishimura S., Takahashi M., Ota S., et al. Hepatocyte growth factor accelerates restitution of intestinal epithelial cells. J Gastroenterol 1998, 33:172-178.
89. Schwartz M.Z., Kato Y., Yu D., et al. Growth-factor enhancement of compromised gut function following massive small-bowel resection. Pediatr Surg Int 2000, 16:174-175.
90. Jeschke M.G., Bolder U., Finnerty C.C., et al. The effect of hepatocyte growth factor on gut mucosal apoptosis and proliferation, and cellular mediators after severe trauma. Surgery 2005, 138:482-489.
91. Kuenzler K.A., Pearson P.Y., Schwartz M.Z. Hepatocyte growth factor pretreatment reduces apoptosis and mucosal damage after intestinal ischemia-reperfusion. J Pediatr Surg 2002, 37:1093-1097.
92. Tahara Y., Ido A., Yamamoto S., et al. Hepatocyte growth factor facilitates colonic mucosal repair in experimental ulcerative colitis in rats. J Pharmacol Exp Ther 2003, 307:146-151.
93. Numata M., Ido A., Moriuchi A., et al. Hepatocyte growth factor facilitates the repair of large colonic ulcers in 2,4,6-trinitrobenzene sulfonic acid-induced colitis in rats. Inflamm Bowel Dis 2005, 11:551-558.
94. Ohda Y., Hori K., Tomita T., et al. Effects of hepatocyte growth factor on rat inflammatory bowel disease models. Dig Dis Sci 2005, 50:914-921.
95. Mukoyama T., Kanbe T., Murai R., et al. Therapeutic effect of adenoviral-mediated hepatocyte growth factor gene administration on TNBS-induced colitis in mice. Biochem Biophys Res Commun 2005, 329:1217-1224.
96. Kanbe T., Murai R., Mukoyama T., et al. Naked gene therapy of hepatocyte growth factor for dextran sulfate sodium-induced colitis in mice. Biochem Biophys Res Commun 2006, 345:1517-1525.
97. Hanawa T., Suzuki K., Kawauchi Y., et al. Attenuation of mouse acute colitis by naked hepatocyte growth factor gene transfer into the liver. J Gene Med 2006, 8:623-635.
98. Oh K., Iimuro Y., Takeuchi M., et al. Ameliorating effect of hepatocyte growth factor on inflammatory bowel disease in a murine model. Am J Physiol Gastrointest Liver Physiol 2005, 288:G729-G735.
99. Sakata H., Takayama H., Sharp R., et al. Hepatocyte growth factor/scatter factor overexpression induces growth, abnormal development, and tumor formation in transgenic mouse livers. Cell Growth Differ 1996, 7:1513-1523.
100. Higashiyama S., Abraham J.A., Miller J., et al. A heparin-binding growth factor secreted by macrophage-like cells that is related to EGF. Science 1991, 251:936-939.
101. vis-Fleischer K.M., Besner G.E. Structure and function of heparin-binding EGF-like growth factor (HB-EGF). Front Biosci 1998, 3:d288-d299.
102. Cribbs R.K., Harding P.A., Luquette M.H., et al. Endogenous production of heparin-binding EGF-like growth factor during murine partial-thickness burn wound healing. J Burn Care Rehabil 2002, 23:116-125.
103. Michalsky M.P., Kuhn A., Mehta V., et al. Heparin-binding EGF-like growth factor decreases apoptosis in intestinal epithelial cells in vitro. J Pediatr Surg 2001, 36:1130-1135.
104. Pillai S.B., Turman M.A., Besner G.E. Heparin-binding EGF-like growth factor is cytoprotective for intestinal epithelial cells exposed to hypoxia. J Pediatr Surg 1998, 33:973-978.
105. Kuhn M.A., Xia G., Mehta V.B., et al. Heparin-binding EGF-like growth factor (HB-EGF) decreases oxygen free radical production in vitro and in vivo. Antioxid Redox Signal 2002, 4:639-646.
106. Xia G., Martin A.E., Michalsky M.P., et al. Heparin-binding EGF-like growth factor preserves crypt cell proliferation and decreases bacterial translocation after intestinal ischemia/reperfusion injury. J Pediatr Surg 2002, 37:1081-1087.
107. Feng J., Besner G.E. Heparin-binding epidermal growth factor-like growth factor promotes enterocyte migration and proliferation in neonatal rats with necrotizing enterocolitis. J Pediatr Surg 2007, 42:214-220.
108. El-Assal O.N., Radulescu A., Besner G.E. Heparin-binding EGF-like growth factor preserves mesenteric microcirculatory blood flow and protects against intestinal injury in rats subjected to hemorrhagic shock and resuscitation. Surgery 2007, 142:234-242.
109. Brubaker P.L., Drucker D.J. Minireview: glucagon-like peptides regulate cell proliferation and apoptosis in the pancreas, gut, and central nervous system. Endocrinology 2004, 145:2653-2659.
110. Scott R.B., Kirk D., MacNaughton W.K., et al. GLP-2 augments the adaptive response to massive intestinal resection in rat. Am J Physiol 1998, 275:G911-G921.
111. Sigalet D.L., Martin G.R. Hormonal therapy for short bowel syndrome. J Pediatr Surg 2000, 35:360-363.
112. Alavi K., Schwartz M.Z., Palazzo J.P., et al. Treatment of inflammatory bowel disease in a rodent model with the intestinal growth factor glucagon-like peptide-2. J Pediatr Surg 2000, 35:847-851.
113. L'Heureux M.C., Brubaker P.L. Glucagon-like peptide-2 and common therapeutics in a murine model of ulcerative colitis. J Pharmacol Exp Ther 2003, 306:347-354.
114. Boushey R.P., Yusta B., Drucker D.J. Glucagon-like peptide 2 decreases mortality and reduces the severity of indomethacin-induced murine enteritis. Am J Physiol 1999, 277:E937-E947.
115. Cameron H.L., Yang P.C., Perdue M.H. Glucagon-like peptide-2-enhanced barrier function reduces pathophysiology in a model of food allergy. Am J Physiol Gastrointest Liver Physiol 2003, 284:G905-G912.
116. Benjamin M.A., McKay D.M., Yang P.C., et al. Glucagon-like peptide-2 enhances intestinal epithelial barrier function of both transcellular and paracellular pathways in the mouse. Gut 2000, 47:112-119.
117. Kouris G.J., Liu Q., Rossi H., et al. The effect of glucagon-like peptide 2 on intestinal permeability and bacterial translocation in acute necrotizing pancreatitis. Am J Surg 2001, 181:571-575.
118. Chance W.T., Sheriff S., McCarter F., et al. Glucagon-like peptide-2 stimulates gut mucosal growth and immune response in burned rats. J Burn Care Rehabil 2001, 22:136-143.
119. Rajeevprasad R., Alavi K., Schwartz M.Z. Glucagonlike peptide-2 analogue enhances intestinal mucosal mass and absorptive function after ischemia-reperfusion injury. J Pediatr Surg 2000, 35:1537-1539.
120. Drucker D.J., Yusta B., Boushey R.P., et al. Human [Gly2]GLP-2 reduces the severity of colonic injury in a murine model of experimental colitis. Am J Physiol 1999, 276:G79-G91.
121. Burrin D.G., Stoll B., Jiang R., et al. GLP-2 stimulates intestinal growth in premature TPN-fed pigs by suppressing proteolysis and apoptosis. Am J Physiol Gastrointest Liver Physiol 2000, 279:G1249-G1256.
122. Burrin D.G., Stoll B., Guan X., et al. GLP-2 rapidly activates divergent intracellular signaling pathways involved in intestinal cell survival and proliferation in neonatal piglets. Am J Physiol Endocrinol Metab 2007, 292:E281-E291.
123. Jeppesen P.B., Hartmann B., Thulesen J., et al. Glucagon-like peptide 2 improves nutrient absorption and nutritional status in short-bowel patients with no colon. Gastroenterology 2001, 120:806-815.
124. Thim L. Trefoil peptides: a new family of gastrointestinal molecules. Digestion 1994, 55:353-360.
125. Babyatsky M.W., deBeaumont M., Thim L., et al. Oral trefoil peptides protect against ethanol- and indomethacin-induced gastric injury in rats. Gastroenterology 1996, 110:489-497.
126. Cook G.A., Thim L., Yeomans N.D., et al. Oral human spasmolytic polypeptide protects against aspirin-induced gastric injury in rats. J Gastroenterol Hepatol 1998, 13:363-370.
127. Tran C.P., Cook G.A., Yeomans N.D., et al. Trefoil peptide TFF2 (spasmolytic polypeptide) potently accelerates healing and reduces inflammation in a rat model of colitis. Gut 1999, 44:636-642.
128. Taupin D.R., Kinoshita K., Podolsky D.K. Intestinal trefoil factor confers colonic epithelial resistance to apoptosis. Proc Natl Acad Sci U S A 2000, 97:799-804.
129. Sands B.E., Podolsky D.K. The trefoil peptide family. Annu Rev Physiol 1996, 58:253-273.
130. Mashimo H., Wu D.C., Podolsky D.K., et al. Impaired defense of intestinal mucosa in mice lacking intestinal trefoil factor. Science 1996, 274:262-265.
131. Shi L., Zhang B.H., Yu H.G., et al. Intestinal trefoil factor in treatment of neonatal necrotizing enterocolitis in the rat model. J Perinat Med 2007, 35:443-446.
132. Vandenbroucke K., Hans W., Van H.J., et al. Active delivery of trefoil factors by genetically modified Lactococcus lactis prevents and heals acute colitis in mice. Gastroenterology 2004, 127:502-513.
133. Beck P.L., Wong J.F., Li Y., et al. Chemotherapy- and radiotherapy-induced intestinal damage is regulated by intestinal trefoil factor. Gastroenterology 2004, 126:796-808.
134. Sun Y.M., Wu W.M., Zhang Y.M., et al. Intestinal trefoil factor produced in Escherichia coli promotes the healing of rat burn-induced acute gastric mucosal lesions. J Trauma 2008, 65:163-169. [article].
135. Yong S., Wu W., Zhang Y., et al. Stability analysis of recombinant human TFF2 and its therapeutic effect on burn-induced gastric injury in mice. Burns 2009, 35:869-874.
136. Cibrian D., Ajamieh H., Berlanga J., et al. Use of growth-hormone-releasing peptide-6 (GHRP-6) for the prevention of multiple organ failure. Clin Sci (Lond) 2006, 110:563-573.
137. Jacobs D.O., Evans D.A., Mealy K., et al. Combined effects of glutamine and epidermal growth factor on the rat intestine. Surgery 1988, 104:358-364.
138. Ko T.C., Beauchamp R.D., Townsend C.M., et al. Glutamine is essential for epidermal growth factor-stimulated intestinal cell proliferation. Surgery 1993, 114:147-153.
139. Zhang W., Bain A., Rombeau J.L. Insulin-like growth factor-I (IGF-I) and glutamine improve structure and function in the small bowel allograft. J Surg Res 1995, 59:6-12.
140. Byrne T.A., Morrissey T.B., Nattakom T.V., et al. Growth hormone, glutamine, and a modified diet enhance nutrient absorption in patients with severe short bowel syndrome. JPEN J Parenter Enteral Nutr 1995, 19:296-302.